

Sarah L Sammons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8421199/publications.pdf>

Version: 2024-02-01

23
papers

250
citations

1307594

7
h-index

996975

15
g-index

24
all docs

24
docs citations

24
times ranked

495
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Metastatic breast cancer: Who benefits from surgery?. American Journal of Surgery, 2022, 223, 81-93. | 1.8 | 6 |
| 2 | Abstract P4-10-06: Best quality care from a distance (BQual-D): Maintaining high quality care for hormone receptor positive (HR+) metastatic breast cancer (MBC) during the COVID pandemic, description of the program and provider satisfaction. Cancer Research, 2022, 82, P4-10-06-P4-10-06. | 0.9 | 0 |
| 3 | Abstract PD14-09: APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD). Cancer Research, 2022, 82, PD14-09-PD14-09. | 0.9 | 1 |
| 4 | Systemic management of brain metastases in HER2+ breast cancer in 2022.. Clinical Advances in Hematology and Oncology, 2022, 20, 325-336. | 0.3 | 0 |
| 5 | Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Expert Review of Anticancer Therapy, 2022, 22, 805-814. | 2.4 | 2 |
| 6 | Abstract PS13-33: Feasibility of a comprehensive monitoring protocol for the prevention and treatment of interstitial lung disease in patients undergoing treatment with fam-trastuzumab deruxtecan. Cancer Research, 2021, 81, PS13-33-PS13-33. | 0.9 | 2 |
| 7 | Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.. Journal of Clinical Oncology, 2021, 39, 1091-1091. | 1.6 | 5 |
| 8 | Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).. Journal of Clinical Oncology, 2021, 39, 1041-1041. | 1.6 | 0 |
| 9 | Real-world Evidence of Diagnostic Testing and Treatment Patterns in US Patients With Breast Cancer With Implications for Treatment Biomarkers From RNA Sequencing Data. Clinical Breast Cancer, 2021, 21, e340-e361. | 2.4 | 10 |
| 10 | Advances in the management of breast cancer brain metastases. Neuro-Oncology Advances, 2021, 3, v63-v74. | 0.7 | 10 |
| 11 | Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR+/HER2+ Breast Cancer. Clinical Breast Cancer, 2020, 20, 1-11. | 2.4 | 20 |
| 12 | Receptor discordance in breast cancer brain metastases: when knowledge is power. Neuro-Oncology, 2020, 22, 1060-1061. | 1.2 | 3 |
| 13 | The Dysregulated Pharmacology of Clinically Relevant <i>ESR1</i> Mutants is Normalized by Ligand-activated WT Receptor. Molecular Cancer Therapeutics, 2020, 19, 1395-1405. | 4.1 | 26 |
| 14 | The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part I: Early-Stage Disease. Drugs and Aging, 2020, 37, 331-348. | 2.7 | 3 |
| 15 | The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients—Part II: Metastatic Disease. Drugs and Aging, 2020, 37, 349-358. | 2.7 | 3 |
| 16 | Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer. Targeted Oncology, 2019, 14, 1-12. | 3.6 | 12 |
| 17 | Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34. | 0.9 | 2 |
| 18 | The Promise of Immunotherapy for Breast Cancer Brain Metastases. Current Breast Cancer Reports, 2019, 11, 241-247. | 1.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype. <i>Clinical Breast Cancer</i> , 2018, 18, 410-417. | 2.4 | 24 |
| 20 | Immune Checkpoint Inhibition. , 2018, , 315-353. | | 0 |
| 21 | Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. <i>Neuro-Oncology</i> , 2017, 19, 1391-1397. | 1.2 | 28 |
| 22 | HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. <i>Current Cancer Drug Targets</i> , 2017, 17, 637-649. | 1.6 | 65 |
| 23 | Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i> ^{V600} mutated melanoma. <i>Melanoma Management</i> , 2016, 3, 207-216. | 0.5 | 21 |